131 results on '"MS Endocriene Oncologie"'
Search Results
2. The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([68Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study
3. Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors
4. Lived experiences of undergoing regular tumor screening in patients with multiple endocrine neoplasia types 1 and 2 (MEN1/MEN2)
5. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites
6. Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study
7. Blood-based proteomic signatures associated with MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression
8. Precision radiotherapy using MR-linac for pancreatic neuroendocrine tumors in MEN1 patients (PRIME): a protocol for a phase I-II trial, and systematic review on available evidence for radiotherapy of pNETs
9. Diagnostic Utility of Menin Immunohistochemistry in Patients With Multiple Endocrine Neoplasia Type 1 Syndrome
10. Prognostic Value of Microscopic Tumor Necrosis in Adrenal Cortical Carcinoma
11. Status of Surveillance and Nonsurgical Therapy for Small Nonfunctioning Pancreatic Neuroendocrine Tumors
12. Lifestyle Factors and Development and Natural Course of Gastroenteropancreatic Neuroendocrine Tumors: A Review of the Literature
13. [18F]mFBG PET/CT imaging outperforms MRI and [68 Ga]Ga-DOTA-TOC PET/CT in identifying recurrence pheochromocytoma.
14. [18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules.
15. NETest: serial liquid biopsies in gastroenteropancreatic NET surveillance
16. ASO Visual Abstract: Primary Tumour Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumours (NET)-A Comparison of Upfront Surgical Resection versus a Watch-and-Wait Strategy in Two Specialist NET Centres
17. Update on the clinical management of multiple endocrine neoplasia type 1
18. Primary Tumor Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumors (NETs): A Comparison of Upfront Surgical Resection Versus a Watch and Wait Strategy in Two Specialist NET Centers
19. Assessing Outcomes After Adrenalectomy for Primary Aldosteronism - Early is Accurate: Retrospective Cohort Study
20. Four decades of experience with carcinoid heart disease: An analysis of 84 patients
21. Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice
22. The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice
23. Reply to 'von Hippel-Lindau disease integrated care pathway: Centralizing, expanding specialists' theatre, and measuring improvement'
24. Multidisciplinary integrated care pathway for von Hippel–Lindau disease
25. Elevated Serotonin and NT-proBNP Levels Predict and Detect Carcinoid Heart Disease in a Large Validation Study
26. Correction: Lebbink et al. Opposite Incidence Trends for Differentiated and Medullary Thyroid Cancer in Young Dutch Patients over a 30-Year Time Span. Cancers 2021, 13, 5104.: Lebbink et al. Opposite Incidence Trends for Differentiated and Medullary Thyroid Cancer in Young Dutch Patients over a 30-Year Time Span. (Cancers 2021, 13, 5104)
27. FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels
28. Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry
29. Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis
30. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?
31. Risk factors for complications after surgery for pancreatic neuroendocrine tumors
32. A Multinational Pilot Study on Patients’ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ‐C30 and EORTC QLQ‐GINET21 Questionnaires
33. Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center
34. Is There a Role for Biomarkers in Surveillance of Pancreatic Neuroendocrine Neoplasms in Von Hippel-Lindau Disease?
35. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease
36. Metastatic patterns of duodenopancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1
37. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
38. Growth Patterns in Children With Multiple Endocrine Neoplasia Type 2B: Small Stature in Childhood
39. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility
40. Reducing failures in daily medical practice: Healthcare failure mode and effect analysis combined with computer simulation
41. Multiple Endocrine Neoplasia Type 1: Latest Insights
42. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement
43. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets
44. Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study
45. Opposite incidence trends for differentiated and medullary thyroid cancer in young dutch patients over a 30‐year time span
46. A simplified primary aldosteronism surgical outcome score is a useful prediction model when target organ damage is unknown – Retrospective cohort study
47. Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort
48. A blood-based polyamine signature associated with MEN1 duodenopancreatic neuroendocrine tumor progression
49. Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity
50. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: results from the DutchMEN Study Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.